Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.757
Journals
Biomedicines
Special Issues
microRNAs as Biomarkers of Cardiovascular Diseases 2.0
share announcement

Special Issue "microRNAs as Biomarkers of Cardiovascular Diseases 2.0"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 30 September 2023 | Viewed by 818

Special Issue Editor

Dr. Celestino Sardu

E-Mail Website
Guest Editor
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia, 80138 Naples, Italy
Interests: clinical cardiology; myocardial infarction; cardiovascular genetics; clinical electrophysiology; molecular cardiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

microRNAs (miRs) are biomarkers of cardiovascular diseases (CDVs), which have been evaluated for diagnostic approaches and monitoring the responsiveness to medical, interventional, and surgical treatments of patients with CVDs. This has led to the initiation of many clinical trials and to the development of antago-miRs and/or mimic-miRs therapies to block and/or to promote the expression of specific miRs. This Special Issue on miRs and CVDs is therefore a particularly topical addition to the field, providing up-to-date insight into delivery of antago/mimic-miRs, safety-related issues, proof-of-principle in preclinical disease models, clinical trials in CVD patients, and approval of miR therapy-based drugs.

Dr. Celestino Sardu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular diseases
  • microRNAs
  • antago-microRNAs
  • mimic-microRNAs
  • diagnosis
  • therapy

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

get_app
Article
Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by
Maura Brioschi
,
Yuri D’Alessandra
,
Massimo Mapelli
,
Irene Mattavelli
,
Elisabetta Salvioni
,
Sonia Eligini
,
Alice Mallia
,
Veronica Ricci
,
Erica Gianazza
,
Stefania Ghilardi
,
Piergiuseppe Agostoni
and
Cristina Banfi
Biomedicines 2023, 11(4), 1037; https://doi.org/10.3390/biomedicines11041037 - 28 Mar 2023
Viewed by 620
Abstract
Sacubitril/Valsartan, used for the treatment of heart failure (HF), is a combination of two drugs, an angiotensin receptor inhibitor, and a neprilysin inhibitor, which activates vasoactive peptides. Even though its beneficial effects on cardiac functions have been demonstrated, the mechanisms underpinning these effects [...] Read more.
Sacubitril/Valsartan, used for the treatment of heart failure (HF), is a combination of two drugs, an angiotensin receptor inhibitor, and a neprilysin inhibitor, which activates vasoactive peptides. Even though its beneficial effects on cardiac functions have been demonstrated, the mechanisms underpinning these effects remain poorly understood. To achieve more mechanistic insights, we analyzed the profiles of circulating miRNAs in plasma from patients with stable HF with reduced ejection function (HFrEF) and treated with Sacubitril/Valsartan for six months. miRNAs are short (22–24 nt) non-coding RNAs, which are not only emerging as sensitive and stable biomarkers for various diseases but also participate in the regulation of several biological processes. We found that in patients with high levels of miRNAs, specifically miR-29b-3p, miR-221-3p, and miR-503-5p, Sacubitril/Valsartan significantly reduced their levels at follow-up. We also found a significant negative correlation of miR-29b-3p, miR-221-3p, and miR-503-5p with VO2 at peak exercise, whose levels decrease with HF severity. Furthermore, from a functional point of view, miR-29b-3p, miR-221-3p, and miR-503-5p all target Phosphoinositide-3-Kinase Regulatory Subunit 1, which encodes regulatory subunit 1 of phosphoinositide-3-kinase. Our findings support that an additional mechanism through which Sacubitril/Valsartan exerts its functions is the modulation of miRNAs with potentially relevant roles in HFrEF pathophysiology. Full article
(This article belongs to the Special Issue microRNAs as Biomarkers of Cardiovascular Diseases 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop